Evidence map›Paper›PMID 40780726›Full record

ArticleBMJ open2025

Procalcitonin to guide antibiotic use during the first wave of COVID-19 in English and Welsh hospitals: integration and triangulation of findings from quantitative and qualitative sources.

Josie Henley, Lucy Brookes-Howell, Philip Howard, Neil Powell, Mahableshwar Albur, Stuart E Bond, Joanne Euden, Paul Dark, Detelina Grozeva, Thomas P Hellyer and 17 more

Abstract read
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Josie HenleySchool of Social Sciences, Cardiff University, Cardiff, UK HenleyJ@cardiff.ac.uk.ORCID http://orcid.org/0000-0002-2709-900X
Lucy Brookes-HowellCollege of Biomedical and Life Sciences, Cardiff University Centre for Trials Research, Cardiff, Wales, UK.
Philip HowardSchool of Healthcare, University of Leeds, Leeds, UK.
Neil PowellRoyal Cornwall Hospitals NHS Trust, Truro, UK.ORCID http://orcid.org/0000-0002-6113-9810
Mahableshwar AlburMicrobiology, NHS North Bristol NHS Trust, Bristol, England, UK.
Stuart E BondMid Yorkshire Hospitals NHS Trust, Wakefield, UK.
Joanne EudenCollege of Biomedical and Life Sciences, Cardiff University Centre for Trials Research, Cardiff, Wales, UK.ORCID http://orcid.org/0000-0002-2844-6878
Paul DarkDivision of Immunology, Immunity to Infection and Respiratory Medicine, The University of Manchester, Manchester, England, UK.
Detelina GrozevaCollege of Biomedical and Life Sciences, Cardiff University Centre for Trials Research, Cardiff, Wales, UK.ORCID http://orcid.org/0000-0003-3239-8415
Thomas P HellyerTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.ORCID http://orcid.org/0000-0001-5346-7411
Susan HopkinsUK Health Security Agency, London, England, UK.
Martin LlewelynGlobal Health and Infectious Diseases, University of Sussex, Brighton, UK.
Wakunyambo MabosheCollege of Biomedical and Life Sciences, Cardiff University Centre for Trials Research, Cardiff, Wales, UK.
Iain J McCullaghCritical Care Department, Royal Victoria Infirmary, Newcastle upon Tyne, England, UK.
Margaret OgdenCollege of Biomedical and Life Sciences, Cardiff University Centre for Trials Research, Cardiff, Wales, UK.
Philip PallmannCollege of Biomedical and Life Sciences, Cardiff University Centre for Trials Research, Cardiff, Wales, UK.ORCID http://orcid.org/0000-0001-8274-9696
Helena K ParsonsSheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
David G PartridgeSheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Dominick ShawNIHR Leicester Biomedical Research Centre Respiratory Diseases, Leicester, East Midlands, UK.
Bethany ShinkinsUniversity of Leeds Leeds Institute of Health Sciences, Leeds, West Yorkshire, UK.
Tamas SzakmanyDepartment of Anaesthesia, Intensive Care and Pain Medicine, Division of Population Medicine, Cardiff University, Cardiff, UK.ORCID http://orcid.org/0000-0003-3632-8844
Stacy ToddLiverpool University Hospitals NHS Foundation Trust, Liverpool, England, UK.
Robert M WestUniversity of Leeds Leeds Institute of Health Sciences, Leeds, West Yorkshire, UK.ORCID http://orcid.org/0000-0001-7305-3654
Emma Thomas-JonesCollege of Biomedical and Life Sciences, Cardiff University Centre for Trials Research, Cardiff, Wales, UK.ORCID http://orcid.org/0000-0001-7716-2786
Enitan CarrolDepartment of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.ORCID http://orcid.org/0000-0001-8357-7726
Jonathan SandoeDepartment of Microbiology, Leeds General Infirmary, Leeds, England, UK.
PEACH Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo integrate the quantitative and qualitative data collected as part of the PEACH (Procalcitonin: Evaluation of Antibiotic use in COVID-19 Hospitalised patients) study, which evaluated whether procalcitonin (PCT) testing should be used to guide antibiotic prescribing and safely reduce antibiotic use among patients admitted to acute UK National Health Service (NHS) hospitals.

designTriangulation to integrate quantitative and qualitative data. SETTING AND

participantsFour data sources in 148 NHS hospitals in England and Wales including data from 6089 patients.

methodA triangulation protocol was used to integrate three quantitative data sources (survey, organisation-level data and patient-level data: data sources 1, 2 and 3) and one qualitative data source (clinician interviews: data source 4) collected as part of the PEACH study. Analysis of data sources initially took place independently, and then, key findings for each data source were added to a matrix. A series of interactive discussion meetings took place with quantitative, qualitative and clinical researchers, together with patient and public involvement (PPI) representatives, to group the key findings and produce seven statements relating to the study objectives. Each statement and the key findings related to that statement were considered alongside an assessment of whether there was agreement, partial agreement, dissonance or silence across all four data sources (convergence coding). The matrix was then interpreted to produce a narrative for each statement.

objectiveTo explore whether PCT testing safely reduced antibiotic use during the first wave of the COVID-19 pandemic.

resultsSeven statements were produced relating to the PEACH study objective. There was agreement across all four data sources for our first key statement, 'During the first wave of the pandemic (01/02/2020-30/06/2020), PCT testing reduced antibiotic prescribing'. The second statement was related to this key statement, 'During the first wave of the pandemic (01/02/2020-30/06/2020), PCT testing

conclusionThere was agreement between all four data sources on our key finding 'during the first wave of the pandemic (01/02/2020-30/06/2020), PCT testing reduced antibiotic prescribing'. Data, methodological and investigator triangulation, and a transparent triangulation protocol give validity to this finding. TRIAL REGISTRATION NUMBER: ISRCTN66682918.

Indexed as

Anti-Bacterial AgentsAntimicrobial StewardshipCOVID-19ProcalcitoninEnglandFemaleHospitalsHumansMaleQualitative ResearchSARS-CoV-2State MedicineWalesAnti-Bacterial AgentsProcalcitoninAntibioticsCOVID-19Diagnostic microbiologyMethodsProtocols & guidelines

Identifiers

PMID40780726
PMCPMC12336465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.